The trajectory of companies tied to Sildenafil's legacy presents a challenging investment scenario . While the initial success generated substantial returns , generic alternatives have significantly impacted market share . Investing in associated pharmaceutical companies now requires a careful assessment of patent safeguards, evolving healthcare sh